Notice for patisiran (Alnylam Australia Pty Ltd)
Active ingredients
patisiran
Sponsor
Date of review outcome
Lapse date
Type
Orphan drug
Dosage form(s)
Concentrate for solution for infusion
Indication
For the treatment of hereditary transthyretin mediated amyloidosis (hATTR amyloidosis) in patients with polyneuropathy
Therapeutic area
Neurological disorder